IL-4Ralpha / IL-5

Class

Bispecific interleukin-pathway inhibitor

IL-4 receptor alpha (IL-4Rα) is a shared receptor component used by both interleukin-4 and interleukin-13, two signaling proteins central to "type 2" immune responses that drive allergic inflammation, including mucus overproduction, tissue remodeling, and the production of immunoglobulin E antibodies. Interleukin-5 (IL-5) is a separate signaling protein that controls the production, activation, and survival of eosinophils, a type of white blood cell implicated in tissue damage in asthma, eosinophilic esophagitis, and related conditions. A bispecific antibody built to block IL-4Rα and neutralize IL-5 at the same time is designed to interrupt two distinct but overlapping arms of type 2 inflammation with one molecule: the epithelial and antibody-mediated effects that follow IL-4/IL-13 signaling, and the eosinophil-driven effects that follow IL-5 signaling. This dual approach reflects the fact that many allergic and eosinophilic diseases are not driven by a single cytokine, so blocking only one pathway can leave disease activity from the other unaddressed. By targeting both nodes, this class of molecule aims for broader suppression of type 2 inflammation than a selective single-target agent, which is potentially relevant across asthma, atopic dermatitis, chronic rhinosinusitis, and eosinophilic gastrointestinal disorders.